Previous Close | 2.3100 |
Open | 2.3000 |
Bid | 2.3200 x 100 |
Ask | 2.4000 x 100 |
Day's Range | 2.2633 - 2.3800 |
52 Week Range | 2.0800 - 5.0900 |
Volume | |
Avg. Volume | 191,442 |
Market Cap | 142.389M |
Beta (5Y Monthly) | 0.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.3800 |
Earnings Date | Nov 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.80 |
Acumen Pharmaceuticals Inc (ABOS) reports a robust cash runway and faster-than-expected enrollment in its ALTITUDE AD Phase 2 study, despite ongoing operational losses.
Q3 2024 Acumen Pharmaceuticals Inc Earnings Call